Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 1, 2012, Pages 39-46

  Rimsky, Laurence ^a   Vingerhoets, Johan ^a   Van Eygen, Veerle ^a   Eron, Joseph ^b   Clotet, Bonaventura ^c   Hoogstoel, Annemie ^a   Boven, Katia ^d   Picchio, Gaston ^d  

^a TIBOTEC BVBA   (Belgium)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Tibotec   (United States)

Author keywords

efavirenz; N(t)RTI RAMs; NNRTI RAMs; rilpivirine; viral load; virologic failure

Indexed keywords

EFAVIRENZ; RILPIVIRINE;

ADULT; ARTICLE; DOUBLE BLIND PROCEDURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS MUTATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; NITRILES; PHENOTYPE; PYRIMIDINES; TREATMENT FAILURE; YOUNG ADULT;

EID: 83655163698     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823df4da     Document Type: Article

References (26)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services (DHSS); Rockville, MD: AIDSinfo; 2011:1-166. Available at: http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed July 1, 2011.
2. FDA label for EDURANT™ (rilpivirine) tablets [package insert] Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202022s000lbl.pdf. Accessed May 28, 2011.
3. FDA label for COMPLERA™ (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets [package insert]. Foster City, CA: Gildead Sciences, Inc. Available at: http://www.gilead.com/pdf/complera-pi.pdf. Accessed September 12, 2011.
4. Molina JM, Cahn P, Grinsztejn B, et al. For the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
5. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. For the THRIVE Study Group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229-237.
6. Cohen C, Molina JM, Cahn P, et al. on Behalf of the ECHO and THRIVE Study Groups. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised phase III trials comparing TMC278 versus efavirenz in treatment-naïve HIV-1-infected patients [abstract THLBB206] Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.
7. Pozniak AL, Morales-Ramirez J, Katabira E, et al. and TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
8. Balzarini J, Karlsson A, Sardana W, et al. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-. C181I) RT HIV-1 mutants. Proc Natl Acad Sci USA. 1994;91:6599-6603.
9. Tambuyzer L, Nijs S, Daems B, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr. 2011;58:18-22.
10. Vingerhoets J, Rimsky L, Van Eygen V, et al. Screening and baseline mutations in the TMC278 phase III trials ECHO and THRIVE: prevalence and impact on virological response [abstract 41]. Antivir Ther. 2011;16(suppl 1):A51.
11. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54:718-727.
12. Haddad M, Napolitano LA, Paquet AC, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility [abstract 10]. Antivir Ther. 2011;16(suppl 1):A18.
13. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
14. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323-332.
15. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1-F5. (Pubitemid 36106291)
16. Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother. 2011;55:600-607.
17. Hu ZX, Kuritzkes DR. Fitness interactions of RPV and 3TC/FTC resistance mutations-a possible explanation for the association of E138K and M184I in clinical trials [abstract 594] Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA.
18. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS. 2010; 24:503-514.
19. Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000;44:2475-2484. (Pubitemid 30650898)
20. Maserati R, De Silvestri A, Uglietti A, et al. and The ARCA Collaborative Group. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS. 2010;24:1013-1018.
21. Kulkarni R, Babaoglu K, Lansdon EB, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic. 2012;59: 48-55.
22. Hu ZX, Li J, Gallien S, et al. Impact of the interactions of rilpivirine (E138K) and lamivudine/emtricitabine (M184V/I) resistance mutations on viral DNA synthesis and fitness of HIV-1 [abstract 12]. Antivir Ther. 2011;16(suppl 1):A20.
23. Xu H, Oliveira M, Asahchop E, et al. The fitness deficits of M184I/V in HIV reverse transcriptase are compensated by E138K that confers broad cross-resistance to second-generation NNRTIs [abstract 11]. Antivir Ther. 2011;16(suppl 1):A19.
24. Clumeck N. Clinical management and treatment of HIV infected adults in Europe. The European AIDS Clinical Society (EACS) guidelines, Version 6.0. Available at: www.europeanaidsclinicalsociety.org. Accessed July 1, 2011.
25. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4:e4724.
26. Picchio G, Vingerhoets J, Tambuyzer L, et al. Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing [abstract MOPDB105] Presented at: XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria.